Filtered By:
Condition: Dementia
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 4555 results found since Jan 2013.
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Investor Update - September 7, 2023 Category: Pharmaceuticals Source Type: news
Does self-directed learning address gaps in nursing student knowledge of Alzheimer's disease?
Educ Gerontol. 2023;49(8):673-686. doi: 10.1080/03601277.2022.2148445. Epub 2022 Dec 8.ABSTRACTIn the past two decades, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from age-related Alzheimer's disease (AD) have increased. Future nurses will be caring for the rapidly escalating number of older adults facing increased AD risk, yet nursing students' knowledge has been shown to be limited regarding the age-related disease of Alzheimer's (and the most common dementia type) (Aljezawi et al., 2022; Mattos et al., 2015). In this pilot study, a quasi-experimental approach was used to examine undergr...
Source: Educational Gerontology - September 7, 2023 Category: Geriatrics Authors: Tamara Love Lisa Ann Kirk Wiese Vanessa Duncan Herlie Bertrand Source Type: research
Interactive association between insomnia symptoms and sleep duration for the risk of dementia —a prospective study in the Swedish National March Cohort
ConclusionInsomnia and short sleep duration increase the risk of dementia amongst middle-aged to older adults.
Source: Age and Ageing - September 7, 2023 Category: Geriatrics Source Type: research
Edaravone dexborneol ameliorates cognitive impairment by regulating the NF- κB pathway through AHR and promoting microglial polarization towards the M2 phenotype in mice with bilateral carotid artery stenosis (BCAS)
This study aimed to explore the anti-inflammatory effects of Edaravone dexborneol (C.EDA) in a CSVD model. Mice with CSVD showed distinct cognitive decline, as assessed by the Morris water maze (MWM). Pathological staining verified leakage across the blood‒brain barrier (BBB), microglial proliferation, neuronal loss and demyelination. Western blot analysis demonstrated that M1 microglia dominated prophase and released proinflammatory molecules; the aryl hydrocarbon receptor (AHR) was found to participate in modulating nuclear factor-kappa B (NF-κB) signalling activation through tumour necrosis factor receptor-associated...
Source: European Journal of Pharmacology - September 6, 2023 Category: Drugs & Pharmacology Authors: Lei Li Guojun He Mingyu Shi Juehua Zhu Yongqing Cheng Yang Chen Jin Chen Qun Xue Source Type: research
